论文部分内容阅读
目的:观察氟达拉滨(Flud)、阿糖胞苷(Ara-C)及粒细胞集落刺激因子(G-CSF)(FLAG)方案治疗难治、复发性急性白血病(AL)的疗效及不良反应。方法:采用FLAG方案(Flud 50 mg／d,第1～5天,30 min内静脉滴注完毕;Ara-C 2 g／d,第1～5天,滴完Flud 4 h后开始静脉滴注;G-CSF 300μg／d,皮下注射,第0天开始直至白细胞数>1×109／L)治疗8例难治、复发性AL。结果:8例中有4例完全缓解(CR),4例未缓解(NR);中性粒细胞最低时间在用药后4～12 d,持续12～25 d,血小板最低时间在用药后3～10 d,持续14～35 d。结论: FLAG方案治疗难治、复发性AL有较好疗效,为患者进行造血干细胞移植赢得了时机。
OBJECTIVE: To observe the efficacy and adverse effects of fludarabine, Ara-C and granulocyte-colony stimulating factor (FLAG) regimen in treatment of refractory and recurrent acute leukemia (AL) reaction. Methods: FLAG (Flud 50 mg / d, 1st to 5th day, intravenous infusion within 30 min; Ara-C 2 g / d, 1st to 5th day, ; G-CSF 300μg / d, subcutaneous injection, starting from 0 days until the number of white blood cells> 1 × 109 / L) treatment of 8 cases of refractory, recurrent AL. Results: The complete remission (CR) was achieved in 4 of 8 cases and the non-remission in 4 cases. The minimum time of neutrophils was between 4 and 12 days after treatment, lasting 12 to 25 days. The minimum platelet time was 3 ~ 10 d for 14 ~ 35 d. Conclusion: The treatment of refractory and recurrent AL with FLAG regimen has a good curative effect, which has won the opportunity for patients to undergo hematopoietic stem cell transplantation.